• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与1型早产儿视网膜病变严重程度及雷珠单抗治疗反应相关的房水细胞因子水平。

Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.

作者信息

Lyu Jiao, Zhang Qi, Jin Haiying, Xu Yu, Chen Chunli, Ji Xunda, Zhang Xiang, Rao Yuqing, Zhao Peiquan

机构信息

Department of Ophthalmology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, 1665 Kong Jiang Road, Shanghai, 200092, China.

Department of Ophthalmology, Shengli Oilfield Central Hospital, Dongying, Shan Dong Province, China.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1469-1477. doi: 10.1007/s00417-018-4034-5. Epub 2018 Jun 9.

DOI:10.1007/s00417-018-4034-5
PMID:29948178
Abstract

PURPOSE

To determine the aqueous humor levels of cytokines in eyes with type 1 retinopathy of prematurity (ROP) before primary intravitreal injection of ranibizumab (IVR).

METHODS

Forty-nine infants with type 1 ROP (56 eyes of 28 infants in the threshold ROP group and 42 eyes of 21 infants in the type 1 pre-threshold ROP group) received primary IVR and 49 aqueous humor samples were obtained preoperatively. Aqueous humor samples from 15 infants (15 eyes) undergoing congenital cataract surgery were used as controls. The concentrations of 27 cytokines were measured by a multiplex bead assay. Infants with persistent, recurrent, or progressive ROP after IVR were retreated.

RESULTS

The preoperative aqueous levels of 16 cytokines were significantly different among type 1 pre-threshold, threshold ROP, and control groups (P < 0.05). The concentrations of vascular endothelial growth factor (VEGF) (P < 0.001), interferon-γ (P < 0.001), interleukin (IL)-10 (P < 0.001), and IL-12 (P < 0.001) were the highest in the threshold ROP group, less in the type 1 pre-threshold ROP group, and the lowest in the control group. Retreatment was given to 55% of infants with ROP within a 48-week follow-up period after primary IVR. Higher VEGF (hazard ratio [HR] = 1.001, P = 0.001) and macrophage inflammatory protein-1β (HR = 1.085, P = 0.022) levels were independently correlated with ROP retreatment.

CONCLUSIONS

Higher aqueous levels of VEGF and inflammatory cytokines were associated with more severe type 1 ROP and ROP retreatment after primary IVR.

摘要

目的

确定在初次玻璃体内注射雷珠单抗(IVR)前,1型早产儿视网膜病变(ROP)患儿眼内房水中细胞因子的水平。

方法

49例1型ROP患儿(阈值ROP组28例患儿的56只眼,1型阈值前ROP组21例患儿的42只眼)接受了初次IVR,并在术前获取了49份房水样本。将15例接受先天性白内障手术的婴儿(15只眼)的房水样本用作对照。通过多重微珠分析法测量27种细胞因子的浓度。IVR后患有持续性、复发性或进行性ROP的婴儿接受再次治疗。

结果

16种细胞因子的术前房水水平在1型阈值前、阈值ROP和对照组之间存在显著差异(P < 0.05)。血管内皮生长因子(VEGF)(P < 0.001)、干扰素-γ(P < 0.001)、白细胞介素(IL)-10(P < 0.001)和IL-12(P < 0.001)的浓度在阈值ROP组中最高,在1型阈值前ROP组中较低,在对照组中最低。在初次IVR后的48周随访期内,55%的ROP患儿接受了再次治疗。较高的VEGF(风险比[HR] = 1.001,P = 0.001)和巨噬细胞炎性蛋白-1β(HR = 1.085,P = 0.022)水平与ROP再次治疗独立相关。

结论

较高的房水VEGF和炎性细胞因子水平与更严重的1型ROP以及初次IVR后的ROP再次治疗相关。

相似文献

1
Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.与1型早产儿视网膜病变严重程度及雷珠单抗治疗反应相关的房水细胞因子水平。
Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1469-1477. doi: 10.1007/s00417-018-4034-5. Epub 2018 Jun 9.
2
Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.贝伐单抗、雷珠单抗和激光光凝治疗土耳其早产儿视网膜病变的比较。
Curr Eye Res. 2017 Mar;42(3):462-469. doi: 10.1080/02713683.2016.1196709. Epub 2016 Jul 15.
3
Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.玻璃体内注射雷珠单抗治疗早产儿视网膜病变后的无应答和复发情况
Ophthalmic Surg Lasers Imaging Retina. 2016 Dec 1;47(12):1095-1105. doi: 10.3928/23258160-20161130-03.
4
Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.玻璃体内注射雷珠单抗初始治疗后侵袭性早产儿视网膜病变的结局和预后因素
BMC Ophthalmol. 2018 Jun 26;18(1):150. doi: 10.1186/s12886-018-0815-1.
5
Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.玻璃体内注射雷珠单抗单药治疗后早产儿视网膜病变的复发:时间及危险因素
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1719-1725. doi: 10.1167/iovs.16-20680.
6
Reactivation of retinopathy of prematurity after ranibizumab treatment.雷珠单抗治疗后早产儿视网膜病变复发。
Retina. 2015 Apr;35(4):675-80. doi: 10.1097/IAE.0000000000000578.
7
SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.康柏西普玻璃体腔内注射与雷珠单抗治疗早产儿视网膜病变的短期疗效比较。
Retina. 2018 Aug;38(8):1595-1604. doi: 10.1097/IAE.0000000000001763.
8
Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.雷珠单抗注射液作为早产儿视网膜病变患者的一线治疗:解剖学结局及影响因素。
Ophthalmology. 2017 Aug;124(8):1156-1164. doi: 10.1016/j.ophtha.2017.03.018. Epub 2017 Apr 12.
9
Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.早产儿视网膜病变经雷珠单抗和康柏西普玻璃体内注射后血清血管内皮生长因子-A 和 B 浓度的变化。
Ophthalmologica. 2023;246(2):81-89. doi: 10.1159/000529393. Epub 2023 Jan 27.
10
FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.早产儿视网膜病变患儿接受玻璃体内贝伐单抗或雷珠单抗治疗后的再激活相关因素。
Retina. 2021 Nov 1;41(11):2261-2268. doi: 10.1097/IAE.0000000000003196.

引用本文的文献

1
Determination of miRNA in tear extracellular vesicles significantly associated with treatment-requiring retinopathy of prematurity: a pilot study.泪液细胞外囊泡中与需要治疗的早产儿视网膜病变显著相关的微小RNA的测定:一项初步研究。
Sci Rep. 2025 Aug 20;15(1):30511. doi: 10.1038/s41598-025-15856-2.
2
Retinopathy of Prematurity (ROP): An Overview of Biomarkers in Various Samples for Prediction, Diagnosis, and Prognosis.早产儿视网膜病变(ROP):用于预测、诊断和预后的各种样本中生物标志物概述
Clin Ophthalmol. 2025 May 7;19:1515-1530. doi: 10.2147/OPTH.S519292. eCollection 2025.
3
Tear fluid cytokine analysis: a non-invasive approach for assessing retinopathy of prematurity severity.

本文引用的文献

1
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.低剂量玻璃体内注射贝伐单抗治疗早产儿视网膜病变的评估:一项1期剂量研究。
JAMA Ophthalmol. 2017 Jun 1;135(6):654-656. doi: 10.1001/jamaophthalmol.2017.1055.
2
Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.雷珠单抗注射液作为早产儿视网膜病变患者的一线治疗:解剖学结局及影响因素。
Ophthalmology. 2017 Aug;124(8):1156-1164. doi: 10.1016/j.ophtha.2017.03.018. Epub 2017 Apr 12.
3
Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema.
泪液细胞因子分析:评估早产儿视网膜病变严重程度的非侵入性方法。
Jpn J Ophthalmol. 2024 Sep;68(5):482-489. doi: 10.1007/s10384-024-01084-0. Epub 2024 Jul 10.
4
Early detection and correlation of tear fluid inflammatory factors that influence angiogenesis in premature infants with and without retinopathy of prematurity.早期检测和相关性分析对早产儿有无早产儿视网膜病变影响血管生成的泪液炎症因子。
Indian J Ophthalmol. 2023 Nov;71(11):3465-3472. doi: 10.4103/IJO.IJO_3407_22.
5
Association between treatment for retinopathy of prematurity and blood monocyte counts.早产儿视网膜病变治疗与血单核细胞计数的关系。
Jpn J Ophthalmol. 2023 Jul;67(4):382-386. doi: 10.1007/s10384-023-00992-x. Epub 2023 May 4.
6
Systemic Cytokines in Retinopathy of Prematurity.早产儿视网膜病变中的全身细胞因子
J Pers Med. 2023 Feb 5;13(2):291. doi: 10.3390/jpm13020291.
7
The Relationship between the Aqueous VEGF Level and the Severity of Type 1 Retinopathy of Prematurity.房水血管内皮生长因子水平与1型早产儿视网膜病变严重程度的关系。
J Clin Med. 2022 Sep 13;11(18):5361. doi: 10.3390/jcm11185361.
8
Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?利用视网膜吞噬细胞治疗缺血性视网膜病变中的病理性血管新生?
Pflugers Arch. 2022 Jun;474(6):575-590. doi: 10.1007/s00424-022-02695-7. Epub 2022 May 7.
9
Novel Potential Biomarkers for Retinopathy of Prematurity.早产儿视网膜病变的新型潜在生物标志物
Front Med (Lausanne). 2022 Feb 2;9:840030. doi: 10.3389/fmed.2022.840030. eCollection 2022.
10
Beyond Fetal Immunity: A Systematic Review and Meta-Analysis of the Association Between Antenatal Corticosteroids and Retinopathy of Prematurity.超越胎儿免疫:关于产前皮质类固醇与早产儿视网膜病变关联的系统评价和荟萃分析
Front Pharmacol. 2022 Jan 28;13:759742. doi: 10.3389/fphar.2022.759742. eCollection 2022.
玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿后,房水细胞因子水平与黄斑厚度降低相关。
PLoS One. 2017 Mar 27;12(3):e0174340. doi: 10.1371/journal.pone.0174340. eCollection 2017.
4
Efficacy of Primary Intravitreal Ranibizumab for Retinopathy of Prematurity in China.中国玻璃体内注射雷珠单抗治疗早产儿视网膜病变的疗效
Ophthalmology. 2017 Mar;124(3):408-409. doi: 10.1016/j.ophtha.2016.10.032. Epub 2016 Nov 30.
5
RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.玻璃体内注射0.312毫克贝伐单抗治疗重度早产儿视网膜病变的视网膜血管发育:一项纵向荧光素血管造影研究
Retina. 2017 Jan;37(1):97-111. doi: 10.1097/IAE.0000000000001126.
6
Differences in aqueous concentrations of cytokines in paediatric and adult patients with Coats' disease.小儿与成人Coats病患者房水中细胞因子浓度的差异。
Acta Ophthalmol. 2017 Sep;95(6):608-612. doi: 10.1111/aos.13151. Epub 2016 Jun 30.
7
Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.贝伐单抗治疗早产儿视网膜病变时血浆细胞因子谱变化的评估
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1649-54. doi: 10.1167/iovs.15-18528.
8
IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways.白细胞介素-12家族细胞因子:一般特征、致病微生物、受体及信号通路
Acta Microbiol Immunol Hung. 2016 Mar;63(1):1-25. doi: 10.1556/030.63.2016.1.1.
9
Interleukin-6 Stimulates Defective Angiogenesis.白细胞介素-6刺激血管生成缺陷。
Cancer Res. 2015 Aug 1;75(15):3098-107. doi: 10.1158/0008-5472.CAN-15-1227. Epub 2015 Jun 16.
10
Reactivation of retinopathy of prematurity after ranibizumab treatment.雷珠单抗治疗后早产儿视网膜病变复发。
Retina. 2015 Apr;35(4):675-80. doi: 10.1097/IAE.0000000000000578.